Spain is currently leading Europe in clinical trials, with its hospitals, research facilities, and biotech in Madrid and Barcelona.
Spain has proved that there is a way to develop the pharmaceutical industry despite Europe being tossed around by change, whether it be the demand for Chinese biotech or, more lately, the need to please US President Donald Trump.
With favourable tax benefits and a quick regulatory process, Spain has become the leader in European clinical trials.
AstraZeneca Plc, Novartis AG, and Roche Holding AG have expanded their footprint in Spain. Prime Minister Pedro Sanchez wants to draw more. Earlier this year, he got the interests of Johnson & Johnson, Daiichi Sankyo Co., Eli Lilly & Co., and Sanofi.
AstraZeneca has chosen Barcelona to build a new research hub in 2023 because of its healthcare environment and employee quality of life.
It promised the city €800 million and 1000 jobs between 2023 and 2027. After reaching its goal the previous year, AstraZeneca increased its funding to €1.3 billion and doubled its target.
Rick R. Suarez, the business’s president for Spain, stated that the government made it easier to win their goals by helping collaborate with start-ups, scientists, and hospitals in Spain’s state-run systems.
Sanofi plans to build a new research center in Barcelona. But it declined to comment.
Spain has shown that it can win a zero-sum game when businesses decide to invest in them. If incentives shift, pharma companies may have to change their course.
The UK learned this when AstraZeneca abandoned its plans to build a vaccine facility due to the level of public funding. Since AstraZeneca reduced its R&D ambitions at the site, the newly elected Labour government claimed that there was a remarkably minimal difference between its offer and what the firm agreed under the previous Conservative administration.
For critics, it shows how trends change quickly, similar to how the UK fell from high ranking in clinical trials and drug access ten years ago.
On the other hand, Spain is currently leading Europe in clinical trials, with its hospitals, research facilities, and biotech in Madrid and Barcelona.
One important thing to note is funding. The government gives tax credits of 33% for R&D spending made by large companies, which is more than 15% for Europe. Workers relocating to Spain get financial benefits like Beckham law, which allows foreigners to pay lower income tax for a fixed period.
For smaller companies like fertility-focused Oxolife, half of the funding is given by the government. CEO Agnès Arbat stated that Spain is one of the most affordable countries in Europe for clinical research, costing far less than Germany or France.
Many executives talked about Barcelona’s appeal, like Valerie Vanhooren, a Belgian scientist who came for personal reasons and spoke about its excellent research, government assistance, and good hospitals.
Sara Secall, general partner at alternative asset management Inveready, claimed that the life science industry had changed so much in the past ten years since many people have started showing interest in Spain, which previously only local investors showed.
According to Health Secretary Javier Padilla, Spain’s public health system could be the reason for expanding the life science industry. He claimed that despite being run by 17 regional governments, it is one of the most integrated in Europe and ranks within the top 10 countries globally for drug purchases.
Even though Spain’s R&D budget increased by more than 50% between 2017 and 2023, it still falls well short of what Germany, the UK, and Denmark spend concerning gross domestic product (GDP). The wealth generated by Novo Nordisk from its Ozempic weight-loss medication is helping to boost the biotech industry and the economy.
Spain also lags behind Germany, Switzerland, and France, according to Salamanca, as the government procrastinated in adopting approved drugs to save money.
But, the government is working with companies like Johnson & Johnson on funding systems that could help increase investment in basic research. It also plans to accelerate the adoption of new drugs.
The main question is whether Spain can sustain this healthcare boost with conflicting pressures like Trump’s tariffs or China’s untapped scientific potential. For instance, AstraZeneca just revealed plans to build a new research facility in Beijing that will cost $2.5 billion. But, the prime minister of Spain, Pedro Sánchez, is trying his best to meet pharmaceutical CEOs and ask them if they want to continue coming back.
